In January 2025, an observational study of nearly 2 million US military veterans reported a wide range of risks and benefits associated with GLP-1 receptor agonists.[1] The addition of a GLP-1RA to usual care reduced the risk in 42 health outcomes (24%), increased the risk in 19 outcomes (10.86%), and showed no significant association in 114 outcomes (65.14%).[1] Reduced risk included septicemia (0.83), pneumonia (0.84), pneumonitis (0.89), anemia (0.97), muscle pain (0.92), liver failure (0.76), inflammatory bowel disease (0.88), and liver cancer (0.82).[1] On the contrary, the increased risk was related to gastrointestinal disorders and hypotension.[1] GLP-1RAs also reduced the risk of substance abuse, psychotic disorders, seizures, neurocognitive disorders including Alzheimer's disease and dementia, coagulation disorders, cardiometabolic disorders, infectious diseases, and respiratory diseases.[1] Studies such as SELECT and SOUL have confirmed the cardiovascular benefits of semaglutide, including a 14% reduction in cardiovascular mortality.[2]